Table 1.
Characteristics of Research Subjects
| Characteristics | Duration of Trastuzumab Therapy | p value | |||
|---|---|---|---|---|---|
| 6 months | 12 months | ||||
| f | % | f | % | ||
| Age | |||||
| < 35 years | 46 | 57.5 | 18 | 43.9 | 0.35 |
| 35-49 years | 33 | 41.3 | 22 | 53.7 | |
| 50-59 years | 1 | 1.3 | 1 | 2.4 | |
| Tumor Size (T) | |||||
| T1 | 3 | 3.8 | 4 | 9.8 | 0.405 |
| T2 | 31 | 38.8 | 18 | 43.9 | |
| T3 | 20 | 25.0 | 10 | 24.4 | |
| T4 | 26 | 32.5 | 9 | 22.0 | |
| Stage | |||||
| Stage I | 3 | 3.8 | 4 | 9.8 | 0.25 |
| Stage II | 36 | 45.0 | 21 | 51.2 | |
| Stage III | 41 | 51.3 | 16 | 39.0 | |
| Grade | |||||
| I | 13 | 16.3 | 3 | 7.3 | 0.077 |
| II | 53 | 66.3 | 24 | 58.5 | |
| III | 14 | 17.5 | 14 | 34.1 | |
| Nodal status | |||||
| Negative | 4 | 5.0 | 5 | 12.2 | 0.165 |
| Positive | 76 | 95.0 | 36 | 87.8 | |
| Histopathology | |||||
| Ductal carcinoma | 49 | 61.3 | 17 | 41.5 | 0.082 |
| Lobular carcinoma | 15 | 18.8 | 9 | 22.0 | |
| Other types | 16 | 20.0 | 15 | 36.6 | |
| Estrogen Receptor | |||||
| Negative | 60 | 75.0 | 25 | 61.0 | 0.165 |
| Positive | 20 | 25.0 | 16 | 39.0 | |
| Progesteron Receptor | |||||
| Negative | 58 | 72.5 | 30 | 73.2 | 1 |
| Positive | 22 | 27.5 | 11 | 26.8 | |
| KI67 | |||||
| < 14% | 20 | 25.0 | 5 | 12.2 | 0.159 |
| > 14% | 60 | 75.0 | 36 | 87.8 | |
| Status | |||||
| Life | 56 | 70.0 | 36 | 87.8 | 0.052 |
| Death | 24 | 30.0 | 5 | 12.2 | |
| Total | 80 | 100.0 | 41 | 100.0 | |